Are peptides legal? What the FDA actually says

People asking whether a peptide is legal are usually asking one of three separate questions, and the answers differ sharply. Is it legal to sell? Is it legal to possess? Is it legal to prescribe, compound, or administer to a person?

Most research peptides are sold under a “research use only — not for human consumption” label. That phrasing is not a description of quality. It is a legal position that permits sale outside the drug-approval framework, and it is exactly what the seller will point to if the product harms someone. The moment a seller markets a product for human use, makes therapeutic claims, or provides human dosing guidance, they have arguably placed it inside the drug framework — where it is an unapproved new drug.

Possession by an individual is generally not the pressure point; almost none of these compounds are controlled substances. The enforcement pressure falls on manufacture, marketing, and compounding.

Under section 503A of the Federal Food, Drug, and Cosmetic Act, a pharmacy may compound a medicine from a bulk drug substance only in narrow circumstances — broadly, when the substance is the subject of an approved application, appears in a USP monograph, or sits on FDA’s 503A bulks list. FDA sorted the substances that had been nominated for that list into categories while it evaluated them.

Category 2 means FDA identified significant safety risks. Substances in Category 2 are not eligible for compounding under the interim policies. Being absent from Category 2, however, is not the same as being permitted — a substance still has to earn its way onto the bulks list, and none of the peptides discussed here have.

The table below is transcribed from the two tables FDA publishes on its bulk-substances page. The left column is FDA’s own wording. It was last checked against the live page on the date shown at the top of this guide — if you are reading this much later, verify it yourself using the source link at the foot of the page. We would rather you check than trust us.

A withdrawn nomination means nobody is asking FDA to permit the substance for compounding any more. The practical consequence is the opposite of what the celebratory headlines imply: a substance that is neither on the 503A bulks list, nor the subject of an approved application, nor in a USP monograph, cannot lawfully be compounded from bulk. Withdrawal removes the pending question. It does not answer it favourably.

FDA’s stated concerns did not evaporate either. For BPC-157 the agency writes that compounded drugs containing it may pose a risk for immunogenicity for certain routes of administration, may have complexities regarding peptide-related impurities and active-ingredient characterisation, and that it "lacks sufficient information to know whether the drug would cause harm when administered to humans." That sentence is still on FDA’s website today.

An FDA-approved drug has been reviewed for safety and effectiveness, its manufacturing plant has been inspected, and its labelling reflects what was actually demonstrated in trials. You can check any claim of approval yourself in Drugs@FDA and read the resulting label on DailyMed. Semaglutide and tirzepatide are approved drugs. BPC-157, TB-500, CJC-1295, ipamorelin, epitalon, selank and semax are not approved for anything, anywhere in the United States.

Everything outside that category — compounded preparations, and the grey market — asks you to substitute your own diligence for a regulator’s. That is what the source checker is for.

Legality and testability are different questions. Growth-hormone secretagogues, GHRH analogues and numerous peptide hormones appear on the WADA Prohibited List, generally banned at all times, in and out of competition. A “research use only” label offers precisely no protection against an adverse analytical finding. If you compete under any anti-doping code, check the current list before you consider anything on this page.